Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

al hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for six months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

Most common adverse reactions ( > 40%) in adult patients receiving either PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia, and anxiety/emotional lability/irritability. Most common adverse reactions ( > 25%) in pediatric patients receiving PEGINTRON/REBETOL are pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema, and vomiting.

In a study with PEGINTRON/REBETOL (weight-based) combination therapy in adult patients, anemia with weight-based dosing was 29%; however, the majority of these cases were mild and responded to dose reductions. The incidence of serious adverse reactions reported for the weight-based REBETOL group was 12%. In many but not all cases, adverse reactions resolved after dose reduction or discontinuation of therapy. Some patients experienced ongoing or new serious adverse reactions during the 6-month follow-up period. Discontinuations for adverse events were 15% and were related to known interferon effects of psychiatric, systemic (e.g., fatigue, headache), or gastrointestinal adverse reactions. Dose modifications due to adverse reactions occurred in 29% of patients.

Most common adverse reactions with PEGINTRON/REBETOL (weight-based) combination therapy were psychiatric, which occurred among 68-69% of patients. These psychiatric adverse reactions included most commonly depression, irritability, and insomnia, each reported by approximately 30-40% of subjects in all treatment groups. Suicidal behavior (ideati
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... WAYNE, N.J., Dec. 16 MAQUET ... technologies, today announced that it has signed ... Novation, the industry,s leading supply contracting company, ... (EVH) Systems. The VASOVIEW products assist healthcare ... blocked coronary arteries using only small incisions. ...
(Date:12/16/2009)... 16 Naurex Inc., a new clinical ... other CNS disorders based on its novel GFPA ... initiated a Phase I clinical trial of its ... first subjects in the study. GLYX-13, a ... of the NMDA receptor, is initially being developed ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Social Isolation Adversely Affects Breast Cancer 58478 1Social Isolation Adversely Affects Breast Cancer 58478 2Social Isolation Adversely Affects Breast Cancer 58478 3Women fare better than men with metastatic colorectal cancer are hormones helping 3F 58474 1Women fare better than men with metastatic colorectal cancer are hormones helping 3F 58474 2Young adults may outgrow bipolar disorder 58470 1Young adults may outgrow bipolar disorder 58470 2
... Sept. 12 The National Alliance for,Hispanic Health ... called,Hypertension ... Control is in your Hands (Presion ... the goal of raising awareness of hypertension (high,blood ... high blood pressure under control. The Alliance is ...
... to US Label for Trasylol(R) and ... additional safety studies, LEVERKUSEN, ... Renal Drugs Advisory Committee and the Drug,Safety and Risk Management Advisory ... to discuss the risk /benefit profile of,Trasylol(R) (aprotinin injection), a Bayer ...
Other Medicine Technology:Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami 2Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami 3FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R) 2FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R) 3
(Date:12/16/2009)... the families of sick and dying hospitalized children ask ... How do pediatricians respond to such personal requests? While ... help some patients and families cope with serious illness, ... the families and patients who raise the issue of ... issue of Southern Medical Journal , Brandeis and ...
(Date:12/16/2009)... Medical Solutions, a national healthcare staffing agency, is honored to ... as the company’s Recruiters of the Year in Healthcare Traveler ... second consecutive year that Chris has received such honors and ... ... (PRWEB) December 16, 2009 -- Medical Solutions, a national healthcare ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... -- Dale Buchanan, owner of Supreme Ultimate Fitness ... loss contest for his students in the new year. The ... competing for their own prize or against each other. They ... Tri County Humane Society in Boca Raton, FL. ... January 4 and February 28, 2010 I will donate $10 ...
(Date:12/16/2009)... Better access to patient information could improve care, ... Dec. 16 (HealthDay News) -- U.S. physicians support ... concerns exist about privacy problems, two new studies ... family practice and specialist doctors in Massachusetts found ... (HIE) would improve patient quality of care, 70 ...
Breaking Medicine News(10 mins):Health News:Prayer on the hospital floor 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:Pros and Cons of Electronic Medical Records Weighed 2
... FORT WORTH, Texas, Nov. 25 H. Paul Dorman, ... Pharmaceuticals, Inc., has announced that Travis E. Baugh has ... and Chief Operating Officer. , ... a distinguished career as a global operations and financial ...
... Care , , , ... of America ( CMSA ) will host its second Collaborative ... San Antonio in San Antonio, Texas . CPS is supported through ... DMAA: The Care Continuum Alliance, and The American Board of Quality ...
... retail opportunities for fresh roasted fortified coffee. , ... ... first in caffeine and fat burning fresh roasted coffee products, has ... partnership in the coffee industry will push the JavaFit brand ...
... Individuals reporting a history of periodontal disease were ... a risk factor for heart disease, compared to ... according to an American Journal of Cardiology ... from Columbia University Medical Center and NewYork-Presbyterian Hospital, ...
... 25 U.S. Secretary of Labor Elaine L. Chao today ... Advisory Committee on Occupational Safety and Health (NACOSH). The ... 1970, advises the Secretaries of labor and health and human ... , "We appreciate the advisory committee ...
... The Lose For Good(TM) Campaign Reaches $1 Million Dollar Donation ... Banks in Need , , ... WTW ) is pleased to announce the donation of one ... Strength and Action Against Hunger. The donation was made ...
Other Medicine News:Health News:Travis E. Baugh Named President, COO of HEALTHPOINT, Ltd. 2Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 2Health News:2009 Collaborative Practice Summit to Bring Together Health Care Leaders 3Health News:JavaFit, Distributors of Vitamin Infused Fresh Roasted Coffee, Announces Partnership With CLR Roasters 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 2Health News:Presence of gum disease may help dentists and physicians identify risk for cardiovascular disease 3Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 4
The Auto Suture&trade ENDO RETRACT&trade Maxi instrument has application in a variety of general, thoracic, gynecologic, urologic, and endoscopic procedures for temporary retracting of tissue and sma...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: